CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX expanded its strategic collaboration with Regeneron to develop conditionally-activated bispecific cancer therapies using CytomX’s PROBODY and Regeneron’s Veloci-Bi platforms. CytomX will receive an immediate $37 million payment for two newly selected targets, with Regeneron securing an option to select up to six additional future targets.
Key figures
- Upfront payment
- 37000000
- Additional targets option
- 6
- Total potential milestones
- 4000000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.